Lipocine Inc is categorized under Commercial Medical Research in Salt Lake City, UT and active since 2013.
Lipocine Inc was established in 2013, and today employs 1 to 4, earning Unknown per year. This is a Commercial Medical Research business, which does work in the B2B market, and is classified as a Commercial Medical Research, under code number 3254120 by the NAICS.
If you are seeking more information, feel free to contact Mahesh Patel, Chief Executive Officer at the company’s headquarters by writing to 675 South Arapeen Drive # 202, Salt Lake City, Utah UT 84108 or by phoning (801) 994-7383. You can also visit this business on Facebook by going to their profile page at Facebook or on find them on Twitter.
| Business Name: | Lipocine Inc |
| Contact Person: | Mahesh Patel, Chief Executive Officer |
| Address: | 675 South Arapeen Drive # 202, Salt Lake City, Utah 84108 |
| Phone Number: | (801) 994-7383 |
| Website Address: | lipocine.com |
| Annual Revenue (USD): | Unknown |
| Founded: | 2013 |
| Location Type: | Headquarters |
| Employee Number: | 1 to 4 |
| Business Type: | B2B (Business to Business) |
| Business Category: | Commercial Medical Research |
| SIC Code: | 8731 |
| NAICS Code: | 3254120 |
| Share This Business: |
Lipocine Inc was started in 2013 to provide professional Commercial Medical Research under the SIC code 8731 and NAICS code 3254120. Since its inception, the company has gone on to take a total of 1 to 4 personnel under its employment and has achieved earnings of Unknown per annum.
Feel free to contact Mahesh Patel, Chief Executive Officer for inquiries that concern Lipocine Inc by calling the company number (801) 994-7383, as your correspondence is most welcome. Additionally, the physical location of the headquarters of Lipocine Inc can be found at the coordinates 40.75564,-111.827 as well as the street address 675 South Arapeen Drive # 202 in Salt Lake City, Utah 84108.
For its online presence, you may visit Lipocine Inc’s website at lipocine.com and engage with its social media outlets through on Twitter and on Facebook.